PRO-DEX, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
PRO-DEX, INC. (PDEX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of -4.00% for the 12-month period ending 2014-06-30, per its 10-K filed 2015-09-17.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2015-09-17
- PRO-DEX, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2014 was -4.00%.
- PRO-DEX, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2013 was -2.00%, a 166.67% decline from fiscal 2012.
- PRO-DEX, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2012 was 3.00%, a 200.00% increase from fiscal 2011.
- PRO-DEX, INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2011 was 1.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month as first filed |
|---|---|---|
| 2014-06-30 | -4.00% 10-K · filed 2015-09-17 | |
| 2013-06-30 | -2.00% 10-K · filed 2014-09-18 | 2.00% 10-K · filed 2013-09-27 |
| 2012-06-30 | 3.00% 10-K · filed 2013-09-27 | |
| 2011-06-30 | 1.00% 10-K · filed 2012-09-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 | |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |